Aurora Cannabis (TSE:ACB) Rating Lowered to “Strong Sell” at TD Securities

Aurora Cannabis (TSE:ACB) was downgraded by equities research analysts at TD Securities from a “strong-buy” rating to a “strong sell” rating in a report released on Tuesday, Zacks reports.

Several other analysts have also recently weighed in on ACB. BMO Capital Markets upgraded Aurora Cannabis to a “hold” rating in a research note on Wednesday, August 5th. ATB Cormark Capital Markets upped their price objective on Aurora Cannabis from C$5.60 to C$7.00 and gave the company a “tender” rating in a report on Tuesday, October 6th. Finally, TD cut Aurora Cannabis from a “buy” rating to a “sell” rating and lowered their price objective for the stock from C$8.00 to C$7.80 in a research report on Wednesday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of C$6.60.

Aurora Cannabis Trading Up 1.4%

Shares of TSE:ACB opened at C$7.31 on Tuesday. Aurora Cannabis has a 12-month low of C$3.59 and a 12-month high of C$8.75. The stock has a market cap of C$452.91 million, a PE ratio of -3.77 and a beta of 0.64. The business has a 50 day moving average of C$5.76 and a 200-day moving average of C$4.95. The company has a quick ratio of 2.48, a current ratio of 5.36 and a debt-to-equity ratio of 4.30.

Aurora Cannabis (TSE:ACB) last posted its earnings results on Wednesday, August 5th. The company reported C($0.07) EPS for the quarter. The firm had revenue of C$67.55 million during the quarter. Aurora Cannabis had a negative net margin of 9.53% and a negative return on equity of 5.21%. As a group, equities research analysts forecast that Aurora Cannabis will post -0.22 earnings per share for the current year.

Aurora Cannabis News Summary

Here are the key news stories impacting Aurora Cannabis this week:

• Positive Sentiment: Organigram agreed to acquire Aurora in a cash-and-stock transaction valued at about C$561 million, offering C$7.80 per share—a reported 93% premium to Aurora’s unaffected share price. The bid topped Curaleaf’s competing hostile offer by 21%, supporting investor interest in the shares. Article: Organigram outbids Curaleaf with C$561M deal for Aurora Cannabis
• Neutral Sentiment: The C$7.80 offer provides a clear transaction value, but the deal remains subject to completion of the arrangement process; the provided reports do not detail the remaining conditions. Article: Organigram to Acquire Aurora and Establish a Global Cannabis Leader
• Negative Sentiment: TD cut Aurora to “sell” from “buy” and lowered its price target to C$7.80 from C$8.00. The downgrade may weigh on sentiment, even though the new target was cited as implying upside from the share price at the time of the rating. Article: TD stock recommendations

About Aurora Cannabis

Aurora is Opening the World to Cannabis ¿, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company’s adult-use brand portfolio includes Drift , San Raf , Daily Special ¿, Tasty’s ¿, Being and Greybeard . Medical cannabis brands include MedReleaf , CanniMed , Aurora and Whistler Medical Marijuana Corporation , as well as international brands, Pedanios , IndiMed ¿ and CraftPlant ¿.